Analyst Consensus ?
1 unmapped firm rating excluded from the percentages.
Atmos Energy Corporation · ATO · FY2026 Q2 · Calendar Q2 2026
Atmos Energy delivered a modest EPS and revenue beat for FY2026 Q2, supported by strong customer growth in Texas and a favorable regulatory tailwind from Texas Rule 7.7102. Management raised full-year EPS guidance to $8.40–$8.50, citing $155–$165 million in pretax benefits from the rule change and robust through-system earnings from the APT pipeline segment. Despite the raised outlook, the stock traded below the benchmark in the immediate reaction window and drifted roughly 6% lower over subsequent weeks, suggesting the market is weighing regulatory execution risk, commodity-price sensitivity at the Waha hub, and elevated capital spending against the guidance increase.
Atmos Energy Corporation, alongside its subsidiaries, is a U.S.-based enterprise primarily involved in the regulated distribution of natural gas, as well as operating pipeline and storage facilities. The company functions through two core divisions: Distribution, and Pipeline and Storage. The Distribution division manages the regulated delivery and associated sales of natural gas across eight states. This division supplies natural gas to approximately three million customers, encompassing homeowners, businesses, public agencies, and industrial clients.…
1 unmapped firm rating excluded from the percentages.
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 30, 2026. Not an FN2 forecast.
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Truist Securities | Hold | Hold | Maintain | Jul 17, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Jul 14, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Jul 14, 2026 |
| Argus Research | Buy | Buy | Maintain | Jul 2, 2026 |
| Mizuho | Neutral | Neutral | Maintain | May 29, 2026 |
| TD Cowen | Hold | Hold | Maintain | May 15, 2026 |
| Citigroup | Neutral | Neutral | Maintain | May 8, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Apr 21, 2026 |
| UBS | Neutral | Neutral | Maintain | Dec 17, 2025 |
| B of A Securities | Neutral | Buy | Downgrade | Oct 16, 2025 |
| Ladenburg Thalmann | Neutral | Buy | Downgrade | Aug 8, 2025 |
| Wells Fargo | Overweight | Overweight | Maintain | Oct 16, 2024 |
| Credit Suisse | Outperform | Outperform | Maintain | Nov 14, 2022 |
| Goldman Sachs | Neutral | Buy | Downgrade | May 13, 2022 |
| Seaport Global | Neutral | Buy | Downgrade | Apr 7, 2021 |
| Bank of America | Buy | Neutral | Upgrade | Jan 7, 2020 |
| Argus | Buy | Hold | Upgrade | May 5, 2018 |
| BB&T Capital | Buy | Buy | Maintain | Mar 30, 2016 |
| Edward Jones | Buy | Hold | Upgrade | Aug 8, 2014 |
| U.S. Capital Advisors | Hold | Underweight | Upgrade | Mar 19, 2014 |
| Hilliard Lyons | Long Term Buy | Maintain | Aug 10, 2012 | |
| Bank oferica | Buy | Buy | Maintain | May 17, 2012 |
Upside is calculated against the persisted current price $175.69. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Morgan Stanley | Analyst unavailable | $196 | $176.52 | +11.6% | Jul 22, 2026 |
| Barclays | Analyst unavailable | $183 | $179.5 | +4.2% | Jul 14, 2026 |
| Wells Fargo | Constantine Lednev | $200 | $176.2 | +13.8% | Jul 13, 2026 |
| Argus Research | Marie Ferguson | $185 | $174.76 | +5.3% | Jul 2, 2026 |
| Morgan Stanley | Analyst unavailable | $190 | $172.4 | +8.1% | Jun 24, 2026 |
| Mizuho Securities | Gabriel Moreen | $184 | $173.01 | +4.7% | May 29, 2026 |
| Morgan Stanley | Analyst unavailable | $183 | $175.58 | +4.2% | May 21, 2026 |
| Truist Financial | Analyst unavailable | $187 | $176.48 | +6.4% | May 18, 2026 |
| Morgan Stanley | Analyst unavailable | $195 | $184.19 | +11.0% | Apr 21, 2026 |
| Morgan Stanley | Analyst unavailable | $192 | $180.38 | +9.3% | Feb 20, 2026 |
| Barclays | Analyst unavailable | $167 | $168.5 | -4.9% | Jan 27, 2026 |
| Morgan Stanley | Analyst unavailable | $180 | $167.87 | +2.5% | Jan 21, 2026 |
| Barclays | Analyst unavailable | $165 | $168.72 | -6.1% | Jan 15, 2026 |
| UBS | Analyst unavailable | $174 | $168 | -1.0% | Dec 17, 2025 |
| Morgan Stanley | Analyst unavailable | $172 | $170.77 | -2.1% | Dec 16, 2025 |
| Mizuho Securities | Gabriel Moreen | $180 | $171.72 | +2.5% | Dec 2, 2025 |
| Morgan Stanley | Analyst unavailable | $182 | $174.87 | +3.6% | Nov 20, 2025 |
| Morgan Stanley | David Arcaro | $181 | $177.54 | +3.0% | Oct 22, 2025 |
| Barclays | Analyst unavailable | $172 | $174.93 | -2.1% | Oct 9, 2025 |
| Barclays | Analyst unavailable | $175 | $175.75 | -0.4% | Oct 9, 2025 |
| Mizuho Securities | Analyst unavailable | $170 | $169.23 | -3.2% | Sep 26, 2025 |
| Morgan Stanley | Analyst unavailable | $167 | $166.46 | -4.9% | Sep 25, 2025 |
| Argus Research | Marie Ferguson | $172 | $161.82 | -2.1% | Sep 18, 2025 |
| UBS | Analyst unavailable | $159 | $156.2 | -9.5% | Jul 30, 2025 |
| Morgan Stanley | David Arcaro | $156 | $152.39 | -11.2% | Jun 18, 2025 |
| Wells Fargo | Sarah Akers | $156 | $142 | -11.2% | Oct 16, 2024 |
| Mizuho Securities | Gabriel Moreen | $148 | $136.48 | -15.8% | Sep 25, 2024 |
| Wells Fargo | Sarah Akers | $132 | $116.84 | -24.9% | May 14, 2024 |
| Mizuho Securities | Gabriel Moreen | $138 | $116.77 | -21.5% | May 13, 2024 |
| UBS | William Appicelli | $124 | $114.38 | -29.4% | Apr 12, 2024 |
| Mizuho Securities | Gabriel Moreen | $131 | $111.6 | -25.4% | Oct 11, 2023 |
| J.P. Morgan | Analyst unavailable | $115 | $112.39 | -34.5% | Jan 9, 2023 |
| Morgan Stanley | Analyst unavailable | $128 | $116.6 | -27.1% | Dec 15, 2022 |
| Morgan Stanley | Analyst unavailable | $120 | $111.54 | -31.7% | Nov 11, 2022 |
| Barclays | Analyst unavailable | $115 | $111.9 | -34.5% | Jul 18, 2022 |
| Goldman Sachs | Insoo Kim | $113 | $112.09 | -35.7% | May 12, 2022 |
| Mizuho Securities | Analyst unavailable | $131 | $114.58 | -25.4% | Apr 29, 2022 |
| Morgan Stanley | Analyst unavailable | $140 | $118 | -20.3% | Apr 26, 2022 |
| Credit Suisse | Analyst unavailable | $133 | $117.7 | -24.3% | Apr 26, 2022 |
| Morgan Stanley | Analyst unavailable | $139 | $122.28 | -20.9% | Apr 20, 2022 |
Track every rating change on ATO the moment it posts. Free to start.
Start freeFollow ATO with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeAtmos reported FY26 first-half net income of $985 million, with Q2 EPS of $3.47 beating the $3.41 consensus by 1.8% and revenue of $1.96 billion exceeding the $1.94 billion estimate by 1.1%. The company added over 51,000 customers in the past year, including 39,000+ in Texas. Texas House Bill 4384 contributed $94 million to H1 earnings. The final rulemaking of Texas Rule 7.7102 reclassifies post-service carrying costs and adds a $155–$165 million pretax benefit for FY26 without affecting net earnings. The dividend was increased approximately 15% year-over-year, reflecting both a rebasing of earnings and the regulatory impact. Capex reached $2 billion in H1 and remains on track for $4.2 billion in FY26.
Full-year EPS guidance raised to $8.40–$8.50 from the prior outlook, reflecting higher APT through-system earnings, the Rule 7.7102 pretax benefit, and continued customer growth. Management targets an additional $0.08–$0.12 contribution from APT through-system business in H2 FY26 and expects roughly 40% of the $600 million in annualized operating-income increases from 13 pending regulatory filings to be realized in Q3.
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.